ABSTRACT
BACKGROUND: The use of cells as carriers for the delivery of nanoparticles is a promising approach in anticancer therapy, mainly due to their natural properties, such as biocompatibility and non-immunogenicity. Cellular carriers prevent the rapid degradation of nanoparticles, improve their distribution, reduce cytotoxicity and ensure selective delivery to the tumor microenvironment. Therefore, we propose the use of phagocytic cells as boron carbide nanoparticle carriers for boron delivery to the tumor microenvironment in boron neutron capture therapy. RESULTS: Macrophages originating from cell lines and bone marrow showed a greater ability to interact with boron carbide (B4C) than dendritic cells, especially the preparation containing larger nanoparticles (B4C 2). Consequently, B4C 2 caused greater toxicity and induced the secretion of pro-inflammatory cytokines by these cells. However, migration assays demonstrated that macrophages loaded with B4C 1 migrated more efficiently than with B4C 2. Therefore, smaller nanoparticles (B4C 1) with lower toxicity but similar ability to activate macrophages proved to be more attractive. CONCLUSIONS: Macrophages could be promising cellular carriers for boron carbide nanoparticle delivery, especially B4C 1 to the tumor microenvironment and thus prospective use in boron neutron capture therapy.
Subject(s)
Boron Neutron Capture Therapy , Nanoparticles , Boron , Cell Line, Tumor , Nanoparticles/metabolism , MacrophagesABSTRACT
Dendritic cells (DCs), as a link between innate and adaptive immunity, play a pivotal role in maintaining homeostasis of the immune system. The DC population is characterized by heterogeneity; it consists of many subpopulations which, despite their phenotypic and localization differences, play an essential function - they are professional antigen presenting cells. Due to their role, DCs can be utilized in a new cancer treatment strategy. Their main purpose is to generate an anticancer response leading to the elimination of cancer cells. The tumor microenvironment, abundant in immunosuppressive factors (e.g. IL-10, TGF-ß, Arg1, IDO), impairs the proper function of DCs. For this reason, various strategies are necessary for ex vivo preparation of DC-based vaccines and for the support of in vivo DCs to fight against tumors. DC-based vaccines are combined with other forms of immunotherapy (e.g. blockade of immune checkpoint molecules, e.g. PD-1 or CTLA-4) or conventional types of therapies (e.g. chemotherapy). Despite the enormous progress that has been made in anticancer therapy in the past two decades, there are still many unresolved issues regarding the effectiveness of the DCs usage. In this paper we described, in both a mouse and a human subject, a series of DC subpopulations, differentiating in normal conditions or under the influence of cancer microenvironment. We listed factors affecting the quality of the in vivo and ex vivo generations of antitumoral responses, significant from a therapeutic point of view. Moreover, the most important strategies for the use of DCs in anticancer therapies, as well as further developments on this field, have been discussed.
Subject(s)
Adaptive Immunity , Dendritic Cells , Immunotherapy , Neoplasms/therapy , Animals , Dendritic Cells/immunology , Humans , Interleukin-10 , Mice , Neoplasms/immunology , Transforming Growth Factor betaABSTRACT
Under the influence of the various stimuli that activate transcription factors such as cMaf, NFIL3, and ERK, many normal and neoplastic cells are able to produce the same cytokine--IL-10. There is increasing evidence that this cytokine has a significant impact on various aspects of the immune control mechanisms. Therefore, it is important to complete understanding of which factors are responsible for regulation of Il10 gene expression and protein secretion. The influence of IL-10 on cells, as in the case of other cytokines, depends on the presence of the specific receptor. Its expression has been shown, among others, on the surface of antigen-presenting cells (dendritic cells, macrophages, B cells), NK cells, T lymphocytes CD8+ and CD4+ (including Tr1, Th1 and Th2), which play an important role in the development of anti-tumor immunity. Therefore, the role of IL-10 in this process is considered to an increasing extent. There are a number of results showing that IL-10 is involved in the generation of immunosuppression, while others demonstrate immunostimulatory properties of this cytokine. This functional duality of IL-10 is substantial in the context of the regulation of tumor growth, both its promotion and fighting against it.
Subject(s)
Immunomodulation/physiology , Interleukin-10/immunology , Interleukin-10/metabolism , Neoplasms/immunology , Animals , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , B-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Gene Expression Regulation , Humans , Immunologic Factors/metabolism , Interleukin-10/genetics , Killer Cells, Natural/immunology , Macrophages/immunology , Receptors, Interleukin-10/metabolism , Transcription, GeneticABSTRACT
In this research, we developed boron-rich nanoparticles that can be used for boron neutron capture therapy as potential carriers for boron delivery to cancerous tissues. Functionalized carbonated boron nitride nanostructures (CBNs) were successfully synthesized in self-propagating combustion waves in mixtures of high-nitrogen explosives and boron compounds. The products' composition, morphology, and structural features were investigated using Fourier transform infrared spectroscopy, powder X-ray diffraction, low-temperature nitrogen sorption analysis, thermogravimetric analysis, high-resolution scanning electron microscopy, and high-resolution transmission electron microscopy. The extreme conditions prevailing in combustion waves favor the formation of nanosized CBN hollow grains with highly disordered structures that are properly functionalized on the surface and inside the particles. Therefore, they are characterized by high porosity and good dispersibility in water, which are necessary for medical applications. During biological tests, a concentration-dependent effect of the obtained boron nitride preparations on the viability of normal and neoplastic cells was demonstrated. Moreover, the assessment of the degree of binding of fluorescently labeled nanoparticles to selected cells confirmed the relationships between the cell types and the concentration of the preparation at different incubation time points.
ABSTRACT
Dendritic cells (DC) were initially considered as antigen presenting cells participating in the polarization of the immune response. Further understanding of their biology allowed determining their additional functions such as immunoregulatory and cytotoxicity. Until recently natural killer (NK) cells were known as a homogeneous population of lymphocytes capable of non-specific recognizing and eliminating target cells. Now it is widely accepted that NK cells, as a heterogeneous population, may also possess immunomodulatory functions. Moreover, the most recent analysis of the interactions between DC and NK cells revealed the exceptional functions of these cells. As a result of these studies the existence of bitypic cell population was postulated. The distinguishing features of these hybrid cells are: the expression of surface receptors typical for NK cells and DC, the cytotoxic activity, the production of interferons as well as their ability to present antigen after prior stimulation. Despite the lack of strong direct evidence that the same cell can be both cytotoxic and effectively present the antigen at the same time, there are experimental findings suggesting that generated ex vivo bitypic cells may be used in antitumor therapy.
Subject(s)
Dendritic Cells/immunology , Killer Cells, Natural/immunology , Animals , Antigen-Presenting Cells/immunology , Humans , Immunomodulation/immunology , Interferons/biosynthesis , MiceABSTRACT
Macrophages play a critical role in the immune response due to their ability to recognize and remove pathogens, as well as present antigens, which are involved in inflammation, but they are also one of the most abundant immune cell populations present in the tumor microenvironment. In recent years, macrophages have become promising cellular carriers for drug and nanoparticle delivery to the tumor microenvironment, mainly due to their natural properties such as biocompatibility, degradability, lack of immunogenicity, long half-life in circulation, crossing biological barriers, and the possibility of migration and accumulation at a site of inflammation such as a tumor. For the effectiveness of this therapeutic strategy, known as "Trojan horse", it is important that the nanoparticles engulfed by macrophages do not affect their proper functioning. In our review, we discussed how the size, shape, chemical and mechanical properties of nanoparticles influence their internalization by macrophages. In addition, we described the promising research utilizing macrophages, their cell membranes and macrophage-derived exosomes as drug carriers in anticancer therapy. As a prospect of the wider use of this therapeutic strategy, we postulate its future application in boron delivery to the tumor environment in boron neutron capture therapy.
Subject(s)
Boron Neutron Capture Therapy , Nanoparticles , Cell Line, Tumor , Drug Carriers/chemistry , Macrophages , Boron , Nanoparticles/chemistry , Boron Neutron Capture Therapy/methodsABSTRACT
Background: The tumor microenvironment (TME) provides a conducive environment for the growth and survival of tumors. Negative factors present in TME, such as IL-10, may limit the effectiveness of cellular vaccines based on dendritic cells, therefore, it is important to control its effect. The influence of IL-10 on immune cells can be abolished e.g., by using antibodies against the receptor for this cytokine - anti-IL-10R. Furthermore, the anticancer activity of cellular vaccines can be enhanced by modifying them to produce proinflammatory cytokines, such as IL-12, IL-15 or IL-18. Additionally, an immunomodulatory dose of methotrexate and hydroxyethyl starch (HES-MTX) nanoconjugate may stimulate effector immune cells and eliminate regulatory T cells, which should enhance the antitumor action of immunotherapy based on DC vaccines. The main aim of our study was to determine whether the HES-MTX administered before immunotherapy with anti-IL-10R antibodies would change the effect of vaccines based on dendritic cells overproducing IL-12, IL-15, or IL-18. Methods: The activity of modified DCs was checked in two therapeutic protocols - immunotherapy with the addition of anti-IL10R antibodies and chemoimmunotherapy with HES-MTX and anti-IL10R antibodies. The inhibition of tumor growth and the effectiveness of the therapy in inducing a specific antitumor response were determined by analyzing lymphoid and myeloid cell populations in tumor nodules, and the activity of restimulated splenocytes. Results and conclusions: Using the HES-MTX nanoconjugate before immunotherapy based on multiple administrations of anti-IL-10R antibodies and cellular vaccines capable of overproducing proinflammatory cytokines IL-12, IL-15 or IL-18 created optimal conditions for the effective action of these vaccines in murine colon carcinoma MC38 model. The applied chemoimmunotherapy caused the highest inhibition of tumor growth in the group receiving DC/IL-15/IL-15Rα/TAg + DC/IL-18/TAg at the level of 72.4%. The use of cellular vaccines resulted in cytotoxic activity increase in both immuno- or chemoimmunotherapy. However, the greatest potential was observed both in tumor tissue and splenocytes obtained from mice receiving two- or three-component vaccines in the course of combined application. Thus, the designed treatment schedule may be promising in anticancer therapy.
Subject(s)
Cancer Vaccines , Colonic Neoplasms , Cytokines , Animals , Mice , Dendritic Cells , Immunotherapy/methods , Interleukin-10 , Interleukin-12 , Interleukin-15 , Interleukin-18 , Methotrexate/pharmacology , Methotrexate/therapeutic use , Nanoconjugates/therapeutic use , Tumor MicroenvironmentABSTRACT
Background: Understanding the negative impact of the tumor microenvironment on the creation of an effective immune response has contributed to the development of new therapeutic anti-cancer strategies. One such solution is combined therapy consisting of chemotherapeutic administration followed by dendritic cell (DC)-based vaccines. The use of cytostatic leads to the elimination of cancer cells, but can also modulate the tumor milieu. Moreover, great efforts are being made to increase the therapeutic outcome of immunotherapy, e.g. by enhancing the ability of DCs to generate an efficient immune response, even in the presence of immunosuppressive cytokines such as IL-10. The study aimed to determine the effectiveness of combined therapy with chemotherapeutic with immunomodulatory potential - HES-MTX nanoconjugate (composed of methotrexate (MTX) and hydroxyethyl starch (HES)) and DCs with downregulated expression of IL-10 receptor stimulated with tumor antigens (DC/shIL-10R/TAg) applied in MC38 murine colon carcinoma model. Methods: With the use of lentiviral vectors the DCs with decreased expression of IL-10R were obtained and characterized. During in vivo studies MC38-tumor bearing mice received MTX or HES-MTX nanoconjugate as a sole treatment or combined with DC-based immunotherapy containing unmodified DCs or DCs transduced with shRNA against IL-10R (or control shRNA sequence). Tumor volume was monitored during the experiment. One week after the last injection of DC-based vaccines, tumor nodules and spleens were dissected for ex vivo analysis. The changes in the local and systemic anti-tumor immune response were estimated with the use of flow cytometry and ELISA methods. Results and conclusions: In vitro studies showed that the downregulation of IL-10R expression in DCs enhances their ability to activate the specific anti-tumor immune response. The use of HES-MTX nanoconjugate and DC/shIL-10R/TAg in the therapy of MC38-tumor bearing mice resulted in the greatest tumor growth inhibition. At the local anti-tumor immune response level a decrease in the infiltration of cells with suppressor activity and an increase in the influx of effector cells into MC38 tumor tissue was observed. These changes were crucial to enhance the effective specific immune response at the systemic level, which was revealed in the greatest cytotoxic activity of spleen cells against MC38 cells.
Subject(s)
Cancer Vaccines , Carcinoma , Colonic Neoplasms , Animals , Mice , Methotrexate/pharmacology , Methotrexate/therapeutic use , Nanoconjugates/therapeutic use , Tumor Microenvironment , RNA, Small Interfering/genetics , Lymphocyte Activation , Dendritic Cells , Receptors, Interleukin-10/metabolism , Carcinoma/drug therapyABSTRACT
Boron carbide is one of the hardest materials in the world which can be synthesized by various methods. The most common one is a carbothermic or magnesiothermic reduction of B2O3 performed at high temperatures, where the obtained powder still requires grinding and purification. The goal of this research is to present the possibility of synthesizing B4C nanoparticles from elements via vapor deposition and modifying the morphology of the obtained powders, particularly those synthesized at high temperatures. B4C nanoparticles were synthesized in the process of direct synthesis from boron and carbon powders heated at the temperature of 1650 °C for 2 h under argon and characterized by using scanning electron microscopy, transmission electron microscopy, atomic force microscopy, X-ray diffraction analysis, and dynamic light scattering measurements. The physicochemical characteristics of B4C nanoparticles were determined, including the diffusion coefficients, hydrodynamic diameter, electrophoretic mobilities, and zeta potentials. An evaluation of the obtained B4C nanoparticles was performed on several human and mouse cell lines, showing the relation between the cytotoxicity effect and the size of the synthesized nanoparticles. Assessing the suitability of the synthesized B4C for further modifications in terms of its applicability in boron neutron capture therapy was the overarching goal of this research.
ABSTRACT
Methotrexate (MTX) which is one of the longest-used cytostatics, belongs to the group of antimetabolites and is used for treatment in different types of cancer as well as during autoimmune diseases. MTX can act as a modulator enable to create the optimal environment to generate the specific anti-tumor immune response. A novel system for MTX delivery is its conjugation with high-molecular-weight carriers such as hydroxyethyl starch (HES), a modified amylopectin-based polymer applied in medicine as a colloidal plasma volume expander. Such modification prolongs the plasma half-life of the HES-MTX nanoconjugate and improves the distribution of the drug in the body. In the current study, we focused on evaluating the dose-dependent therapeutic efficacy of chemotherapy with HES-MTX nanoconjugate compared to the free form of MTX, and examining the time-dependent changes in the local and systemic anti-tumor immune response induced by this therapy. To confirm the higher effectiveness of HES-MTX in comparison to MTX, we analyzed its action using murine MC38 colon carcinoma and B16 F0 melanoma tumor models. It was noted that HES-MTX at a dose of 20 mg/kg b.w. was more effective in tumor growth inhibition than MTX in both tumor models. One of the main differences between the two analyzed tumor models concerned the kinetics of the appearance of the immunomodulation. In MC38 tumors, the beneficial change in the tumor microenvironment (TME) landscape, manifested by the depletion of pro-tumor immune cells, and increased influx of cells with strong anti-tumor activity was noted already 3 days after HES-MTX administration, while in B16 F0 model, these changes occurred 10 days after the start of therapy. Thus, the immunomodulatory potential of the HES-MTX nanoconjugate may be closely related to the specific immune cell composition of the TME, which combined with additional treatment such as immunotherapies, would enhance the therapeutic potential of the nanoconjugate.
ABSTRACT
The main purpose of our study was to determine the effect of dendritic cell (DC) transduction with lentiviral vectors carrying sequences of il18 and/or il12 genes on the level of antitumor activity in vitro and in vivo. We examined the ability of DCs to migrate to the tumor-draining lymph nodes and infiltrate tumor tissue and to activate the local and systemic antitumor response. On the 15th day, DCs genetically modified for production of IL-12 and/or IL-18 were administered peritumorally to C57BL/6 female mice with established MC38 tumors. Lymphoid organs and tumor tissue were collected from mice on the 3rd, 5th, and 7th days after a single administration of DCs for further analysis. Administration of DCs transduced for production of IL-12 alone and in combination with IL-18 increased the inflow and activity of CD4+ and CD8+ T lymphocytes in the tumor microenvironment and tumor-draining lymph nodes. We also found that even a single administration of such modified DCs could trigger a systemic antitumor response as well as inhibit tumor growth. Application of the developed DC-based vaccines may exert a favorable impact on stimulation of an antitumor immune response, especially if these DC vaccines are administered repeatedly.
Subject(s)
Carcinoma , Interleukin-12 , Animals , Antigens, Neoplasm , Colon , Dendritic Cells , Female , Immunity , Interleukin-12/genetics , Interleukin-18/genetics , Mice , Mice, Inbred C57BL , Tumor MicroenvironmentABSTRACT
A number of distinguished populations with manifold functions and various pathways of differentiation have been identified within T lymphocytes. The cells expressing CD4 coreceptor on their cell surface are the most varied group. Depending on changes in different tissue microenvironments induced by such cytokines as IL-4, IFN-γ, IL-10 or TGF-ß, CD4+ T lymphocytes can differentiate into alternative subpopulations performing helper, regulatory/suppressor function (Th1, Th2, Th9, Th17, Th22, Tfh, iTreg and Tr1). In the direction of lineage differentiation of these lymphocytes, transcription factors play the key role. The most important of them are T-bet, GATA3, RORγt, FOXP3, AHR and c-Maf. A cytokine binding to a specific receptor activates the transcription factors, other DNA-binding proteins, and epigenetic alterations, enabling the transcription of proper genetic information. The plasticity of CD4+ cell differentiation seems to be in dynamic balance between initial commitment and flexibility of these cells in the face of a changing environment. Even more, phenotypical and functional borders between particular subpopulations have turned out to be fluent. Then, the influence of extrinsic factors on the activation of mechanisms responsible for conversion of CD4+ T lymphocytes into functional mature cells appears to be more complicated than was previously thought.
Subject(s)
CD4-Positive T-Lymphocytes/drug effects , Cell Differentiation/drug effects , Transcription Factors/metabolism , Transcription Factors/pharmacology , HumansABSTRACT
Myeloid-derived suppressor cells (MDSCs) are potent suppressors of antitumor immunity and their accumulation is often associated with poor prognosis. The aim of the present study was to determine the mechanisms of action of lentiviral vectors encoding short hairpin (sh)RNA against interleukin-10 (IL-10), with particular emphasis on their influence on the activity of tumor-derived MDSCs. Lentiviral vectors encoding shRNA against IL-10 (shIL-10 LVs) were utilized to silence the expression of IL-10 either in MDSCs that were generated ex vivo from bone marrow cells cultured in the presence of supernatant from MC38 colon carcinoma cells, or in situ in the MC38 murine colon carcinoma environment. Although monocytic MDSCs (M-MDSCs) transduced with shIL-10 LVs exhibited increased suppressor activity, transduction of polymorphonuclear MDSCs (PMN-MDSCs) appeared to reduce their ability to inhibit T lymphocyte functions. Analysis of EGFP expression in MC38 tumors revealed that intratumorally inoculated shIL-10 LVs transduced tumor-infiltrating myeloid cells with the highest efficiency and, led to a decreased IL-10 level in the tumor microenvironment. However, the effect was accompanied by increased influx of PMN-MDSCs into tumors observed both on the 6th and on the 10th day after shIL-10 LV injections. Nevertheless, it was noted that suppressor activity of myeloid cells isolated from tumors was dependent on the efficiency of tumor-derived PMN-MDSC transduction with shIL-10 LVs. The increased percentage of transduced PMN-MDSCs on the 10th day was associated with diminished immunosuppressive activity of tumor-derived myeloid cells and an elevated ratio of cytotoxic T lymphocytes to M-MDSCs. The obtained data indicated that treatment with shIL-10 LVs may result in modulation of the immunosuppressive activity of MC38 colon carcinoma-derived MDSCs.
ABSTRACT
The aim of the work was to study the interaction between boron-rich boron carbide nanoparticles and selected tumor and immune phagocytic cells. Experiments were performed to investigate the feasibility of the application of boron carbide nanoparticles as a boron carrier in boron neutron capture therapy. Boron carbide powder was prepared by the direct reaction between boron and soot using the transport of reagents through the gas phase. The powder was ground, and a population of nanoparticles with an average particle size about 80 nm was selected by centrifugation. The aqueous suspension of the nanoparticles was functionalized with human immunoglobulins or FITC-labeled human immunoglobulins and was then added to the MC38 murine colon carcinoma and to the RAW 264.7 cell line of mouse macrophages. Flow cytometry analysis was used to determine interactions between the functionalized boron carbide nanoparticles and respective cells. It was shown that B4C-IgG nanoconjugates may bind to phagocytic cells to be internalized by them, at least partially, whereas such nanoconjugates can only slightly interact with molecules on the cancer cells' surface.
ABSTRACT
Chemotherapy with lowmolecular weight compounds, despite elimination of cancer cells, entails adverse effects. To overcome this disadvantage, innovative drug delivery systems are being developed, including conjugation of macromolecular carriers with therapeutics, e.g. a nanoconjugate of hydroxyethyl starch and methotrexate (HESMTX). The purpose of the present study was to determine whether HESMTX, applied as a chemotherapeutic, is able to modulate the immune response and support the antitumor response generated by dendritic cells (DCs) used subsequently as immunotherapeutic vaccines. Therefore, MTX or HESMTX was administered, as sole treatment or combined with DCbased vaccines, to MC38 colon carcinoma tumorbearing mice. Alterations in antitumor immune response were evaluated by multiparameter flow cytometry analyses and functional assays. The results demonstrated that the nanoconjugate possesses greater immunomodulatory potential than MTX as reflected by changes in the landscape of immune cells infiltrating the tumor and increased cytotoxicity of splenic lymphocytes. In contrast to MTX, therapy with HESMTX as sole treatment or combined with DCbased vaccines, contributed to significant tumor growth inhibition. However, only treatment with HESMTX and DCbased vaccines activated the systemic specific antitumor response. In conclusion, due to its immunomodulatory properties, the HESMTX nanoconjugate could become a potent anticancer agent used in both chemo and chemoimmunotherapeutic treatment schemes.
Subject(s)
Cancer Vaccines/administration & dosage , Carcinoma/therapy , Colonic Neoplasms/therapy , Dendritic Cells/immunology , Drug Carriers/chemistry , Methotrexate/administration & dosage , Animals , Cancer Vaccines/immunology , Carcinoma/immunology , Carcinoma/pathology , Cell Line, Tumor/transplantation , Colon/drug effects , Colon/immunology , Colon/pathology , Colonic Neoplasms/immunology , Colonic Neoplasms/pathology , Combined Modality Therapy/methods , Disease Models, Animal , Female , Humans , Hydroxyethyl Starch Derivatives/chemistry , Intestinal Mucosa/drug effects , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Mice , Nanoconjugates/chemistry , Tumor Escape/drug effectsABSTRACT
The one of the main modes of homeostasis protection is maintaining the balance between antimicrobial immunological reactions and mechanisms involved in immune response suppression. The interaction between dendritic and T cells plays a crucial role in inducing both an immune response and immunological tolerance. Dendritic cells are also able to affect the differentiation, migration, and activation of CD4+ T cells using cell-to-cell contact and/or cytokine production. The proper cytokine microenvironment can influence the induction of FoxP3 transcription factor in T cells, determining the regulatory properties of these cells. However, it is still unclear what is more substantial for Treg induction: the cytokines in the microenvironment, stimulation by a specific DC population, or the type of antigens presented by DC. Activated natural Treg as well as induced Treg cells use similar mechanisms to generate tolerance, for example by the production of such anti-inflammatory cytokines as TGF-beta or IL-10 and by direct contact with target cells. Recently, some reports have described the possibility that Treg cells lose FoxP3 expression followed by loss of suppressive function directed against proliferating T lymphocytes.
Subject(s)
Dendritic Cells/immunology , Homeostasis/immunology , T-Lymphocytes, Regulatory/immunology , HumansABSTRACT
Lipopolysaccharides are the main surface antigens and virulence factors of gramnegative bacteria. Removal of four esterbound fatty acid residues from hexaacyl lipid A of Escherichia coli lipooligosaccharide (LOS) resulted in the deOacylated derivative E. coli LOSOH (LOSOH). This procedure caused a significant reduction in the toxicity of this compound compared to the native molecule. We investigated the effect of such a structural LOS modification on its biological activity using in vitro assays with monocytic cells of the RAW264.7 line, dendritic cells of the JAWS II line, bone marrowderived dendritic cells (BMDCs), and spleen cells. Furthermore, in in vivo experiments with a melanoma B16 metastasis model, the antimetastatic activity of the compounds and spleen cell reactivity mediated by them representing a systemic response were analyzed. The results revealed that LOSOH demonstrated weaker ability than LOS to stimulate and polarize an immune response both in vitro and in vivo. It induced lower cytokine production by cells of myeloid lines. Multiple applications of LOSOH into mice injected intravenously with B16 cells significantly (P<0.05; P<0.01) reduced the number of metastatic foci in the lungs, presumably via silencing of myeloid cell reactivity as well as the inability to stimulate lymphoid cells both directly and indirectly. These findings suggest that LOSOH maintained in the body of metastasisbearing mice appears to modulate or downregulate the innate response, leading to the inability of blood myeloid cells to support the migration of melanoma cells to lung tissue.
Subject(s)
Escherichia coli/metabolism , Lipid A/administration & dosage , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Melanoma, Experimental/drug therapy , Animals , Cell Line, Tumor , Escherichia coli Proteins/administration & dosage , Escherichia coli Proteins/pharmacology , Female , Humans , Injections, Intravenous , Lipid A/chemistry , Lipid A/pharmacology , Lung Neoplasms/immunology , Melanoma, Experimental/immunology , Mice , RAW 264.7 Cells , Tumor Escape/drug effects , Xenograft Model Antitumor AssaysABSTRACT
We have examined the effect of IL-12-producing cellular vaccines on the cytotoxicity and proliferative potential of CD45+ tumour-infiltrating cells (TIL) in mice carrying syngeneic TC-1 and TC-1/A9 HPV 16-associated tumours after chemotherapy with CBM-4A ifosfamide derivative. The chemotherapy resulted in the decrease of the CD4+ and CD8+ TIL, increase of the Gr-1+/CD11b+ TIL, no changes in the infiltration with CD4+/CD25+ Treg TIL, and decrease of the cytolytic and proliferative potential of the CD45+ TIL. Subsequent immunotherapy with the IL-12-producing, genetically modified TC-1 (TC-1-IL-12) cells increased tumour infiltration with CD8+ and CD4+ cells, decreased the Gr-1+/CD11b+ cells, and increased the cytolytic and proliferative potential of the CD45+ TIL. Taken together, these findings suggest that peritumoral administration of the IL-12-producing cellular vaccine can restore the cytolytic potential and inhibit immunosuppressive TIL-dependent mechanisms in the individuals bearing HPV 16-associated tumours, and explain our previously described tumour-inhibitory effects of the vaccine in mice with minimal residual disease after the tumour chemotherapy.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Cell Proliferation , Human papillomavirus 16/pathogenicity , Interleukin-12/physiology , Lymphocytes, Tumor-Infiltrating/immunology , Neoplasms, Experimental/immunology , Papillomavirus Infections/immunology , Animals , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cytotoxicity Tests, Immunologic , Flow Cytometry , Genetic Therapy , Humans , Ifosfamide/analogs & derivatives , Ifosfamide/therapeutic use , Immunoenzyme Techniques , Immunotherapy , Male , Mice , Mice, Inbred C57BL , Neoplasms, Experimental/therapy , Neoplasms, Experimental/virology , Papillomavirus Infections/therapy , Papillomavirus Infections/virology , Tumor Cells, CulturedABSTRACT
The use of dendritic cells (DCs) loaded with tumour antigen is one of the most promising approaches to induce tumour-specific immune response. However, methods of the vaccine preparation have not yet been standardized. The purpose of the study was to analyse the anti-tumour efficacy of tumour antigen-loaded mouse bone marrow-derived dendritic cells (BM-DC/TAg) at different maturation stages. BM-DCs were loaded with MC38 colon carcinoma cell lysate (TAg) alone, to become partially differentiated, or were additionally stimulated with inflammatory cytokines such as TNF-alpha, IFN-gamma, or IL-12 to reach complete maturity. BM-DCs simultaneously stimulated with TAg and cytokines (especially IL-12 or IFN-gamma+IL-12) were in vitro more effective immune response activators than BM-DC/TAg cells. However, the highest anti-tumour effect in vivo was noted when mice were treated just with BM-DC/TAg. In a further study, the ability of IL-12 gene transduced BM-DCs (BM-DC/IL-12) to augment the immune response induced by BM-DC/TAg cells at different stages of maturation was examined. The highest anti-tumour effect was observed when partially differentiated BM-DC/TAg cells were injected simultaneously with BM-DC/IL-12 cells. The results suggest that partially differentiated BM-DC/TAg cells are more potent in evoking a strong anti-tumour response in vivo than mature BM-DCs. Moreover, the capacity of BM-DC/TAg cells for further differentiation and their sensitivity to factors secreted in vivo by the host or cells engineered to cytokine production seem to be of great importance.
Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines , Colonic Neoplasms/therapy , Cytokines/metabolism , Dendritic Cells/transplantation , Immunotherapy, Adoptive , Inflammation Mediators/metabolism , Spleen/immunology , Animals , Cell Differentiation , Cell Line, Tumor , Cells, Cultured , Colonic Neoplasms/immunology , Cytokines/genetics , Dendritic Cells/immunology , Female , Interferon-gamma/metabolism , Interleukin-12/genetics , Interleukin-12/metabolism , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Th1 Cells/immunology , Th2 Cells/immunology , Time Factors , Transduction, Genetic , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Recent developments demonstrate that tumor-derived extracellular vesicles (EVs) could become a highly effective tool for delivery of antitumor factors. The main objective of the study was to determine whether EVs secreted by MC38 colon carcinoma cells genetically engineered for overproduction of interleukin (IL-)12 and/or shRNA targeting TGF-ß1 are effectively loaded with these molecules and whether the obtained EVs could be an efficient tool for antitumor therapy. Fractions of EVs released by genetically modified MC38 cells [both modified tumor-derived exosomes (mTEx) and modified microvesicles (mTMv)] and those released by unmodified, wild-type MC38 cells were characterized in terms of loading efficacy, using real-time PCR and ELISA, as well as their antitumor potential. In order to examine the therapeutic potential of mTEx, they were applied in the form of sole treatment as well as in combination with dendritic cell (DC)-based vaccines stimulated with mTMv in the therapy of mice with subcutaneously growing MC38 tumors. The results demonstrated that genetic modification of wild-type MC38 tumor cells is an effective method of loading the molecules of interest into extracellular vesicles secreted by the cells (both TEx and TMv). The results also showed that mTEx secreted by cells engineered for overproduction of IL-12 and/or shRNA for TGF-ß1 are able to induce tumor growth inhibition as opposed to TEx from unmodified MC38 cells. Additionally, antitumor therapy composed of mTEx (especially those deprived of TGF-ß1) and DC-based vaccines allowed for regeneration of antitumor immunity and induction of the systemic Th1 response responsible for the sustained effect of the therapy. In conclusion, tumor-derived exosomes loaded with IL-12 and/or deprived of TGF-ß1 could become an efficient adjuvant supporting induction of a specific antitumor response in both immuno- and chemotherapeutic schemes of treatment.